- Home
- CWK vs LGND Comparison
CWK vs LGND Comparison
Compare CWK & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- LGND
- Stock Information
- Founded
- CWK 1784
- LGND 1987
- Country
- CWK United States
- LGND United States
- Employees
- CWK N/A
- LGND N/A
- Industry
- CWK Real Estate
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- CWK Finance
- LGND Health Care
- Exchange
- CWK Nasdaq
- LGND Nasdaq
- Market Cap
- CWK 1.9B
- LGND 2.0B
- IPO Year
- CWK 2018
- LGND 1992
- Fundamental
- Price
- CWK $8.28
- LGND $104.97
- Analyst Decision
- CWK Hold
- LGND Strong Buy
- Analyst Count
- CWK 6
- LGND 7
- Target Price
- CWK $12.75
- LGND $144.67
- AVG Volume (30 Days)
- CWK 2.7M
- LGND 127.9K
- Earning Date
- CWK 04-29-2025
- LGND 05-06-2025
- Dividend Yield
- CWK N/A
- LGND N/A
- EPS Growth
- CWK N/A
- LGND N/A
- EPS
- CWK 0.56
- LGND N/A
- Revenue
- CWK $9,446,500,000.00
- LGND $167,133,000.00
- Revenue This Year
- CWK $5.68
- LGND $16.47
- Revenue Next Year
- CWK $5.95
- LGND $19.44
- P/E Ratio
- CWK $14.79
- LGND N/A
- Revenue Growth
- CWK N/A
- LGND 27.28
- 52 Week Low
- CWK $7.64
- LGND $67.72
- 52 Week High
- CWK $16.11
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- CWK 30.38
- LGND 47.85
- Support Level
- CWK $8.09
- LGND $100.30
- Resistance Level
- CWK $8.41
- LGND $107.62
- Average True Range (ATR)
- CWK 0.55
- LGND 6.00
- MACD
- CWK -0.04
- LGND 0.59
- Stochastic Oscillator
- CWK 23.44
- LGND 74.98
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.